bms.com (BMY) - Bathi pungkasan

Government price regulation and potential clinical trial failures remain the primary threats to Bristol-Myers Squibb (BMY). Patents on top-tier drugs and a robust pipeline of new developments ensure business stability. The company's bottom line, as illustrated by this chart on GURU.Markets, reflects the impact of the loss of exclusivity for Eliquis, with the indicator settling at 9.23.

BMY (Bristol Myers Squibb) riwayat Bathi resik perusahaan saka 04.07.2022 nganti 01.11.2026

Rincian metrik keuangan lan pasar Bristol Myers Squibb (BMY)

- nilai pasar lan prakiraan target analis:

Rega saham Bristol-Myers Squibb Co.|BMY - Target konsensus

- indikator kapitalisasi pasar:

Nilai pasar Bristol-Myers Squibb Co.|BMY - Nilai Perusahaan

- rincian valuasi buku bisnis:

Nilai Akuntansi Saham Bristol Myers Squibb|BMY - Nilai Buku Perusahaan|Koefisien Nilai Pasar marang Nilai Buku bms.com|BMY - Aset Agregat Perusahaan

- indikator beban utang lan likuiditas:

Utang marang Ekuitas Bristol-Myers Squibb|BMY - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang modal Bristol Myers Squibb Company|BMY - Gunggung utang perusahaan|Utang-utang marang aset resik Bristol-Myers Squibb Co.|BMY - Utang jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan Bristol Myers Squibb|Likuiditas kritis bms.com

- indikator pendapatan resik lan kelipatan nilai:

BMY - Bathi resik

Pambiji fundamental:BMY - Bristol-Myers Squibb Co.

For Bristol-Myers Squibb (BMY), analyzing returns through the lens of ecological transformation allows for an assessment of business sustainability. This operating result for the company is calculated as a daily interpolation of quarterly earnings, revealing the actual consolidation corridors of profit. The indicator's stable channel confirms financial strength. Investments in green energy and electric fleets may temporarily shift this range. A downward move in the metric signals risks of asset impairment.

Pesaing utama